Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Gemcitabine × Clear all

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04722978 2025-12-17

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

228 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2 Not yet recruiting

29 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

87 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

54 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02996825 2024-04-02

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Phase 1 Completed

44 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

31 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

503 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02341911 2022-04-20

TNBC

Phase 2 Unknown

150 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04517292 2020-08-18

GEP

Phase 2 Unknown

160 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01287624 2015-03-23

TNBC

Phase 3 Completed

240 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

ToPCourT

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

PATHFINDER

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

BELLA

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

TNBC

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

GEP

TNBC